Patients with primary central nervous system (CNS) lymphoma who respond to initial treatment with glucocorticoids appear to have substantially better survival than patients who do not respond. These results were published in the journal Cancer.
Treatment with zoledronic acid can reduce lung metastases and improve survival in mice inoculated with an osteosarcoma cell line, according to a report in the December 22nd issue of Cancer.
According to results recently presented at the 47th annual meeting of the American Society of Hematology (ASH), the vaccine BiovaxID, which is still in clinical trials, appears very promising in the treatment of follicular lymphoma.
According to results recently presented at the 47th annual meeting of the American Society of Hematology (ASH), the agent GX15-070, which is still in clinical trials, has anticancer activity in patients with chronic lymphocytic leukemia (CLL) who have stopped responding to standard therapies including chemotherapy, Rituxan?, and Campath?.
According to a study published in the journal Cancer, second-line treatment (treatment given when initial treatment doesn’t work) with the chemotherapy drugs paclitaxel and carboplatin resulted in a partial reduction of cancer or stable disease in 45% of patients with metastatic melanoma.
According to a recent article published in the Journal of Clinical Oncology, women with lung cancer who have taken hormone replacement therapy (HRT) may have a significantly poorer overall survival than those who have never taken HRT.
According to results presented at the 47th annual meeting of the American Society of Hematology (ASH), patients 60 years of age and over diagnosed with acute myeloid leukemia (AML) do not benefit from increased doses of the commonly used chemotherapy agents daunorubicin (Cerubidine?) or cytarabine (Cytosar-U?); as well, increasing the number of treatment courses of subsequent chemotherapy does not provide benefit.
A comparison of two clinical trials suggests that the chemotherapy drug cisplatin is more effective against metastatic osteosarcoma than the chemotherapy drug carboplatin. These results were published in the journal Cancer.
Each year more than 1 million cases of skin cancer are reported. The most common type of skin cancer is basal cell cancer, which accounts for 80 percent of all skin cancers. The other types of skin cancer includes squamous and melanoma.
According to the American Association of Neurological Surgeons (AANS) between 75 and 85 percent of all Americans will suffer from low back pain at some point in their lives. However lumbar fusion is proving to be highly effective for the 10 percent of patients who require surgery.